Advertisement
Screener

Zoetis Inc. (ZTS) Graph

ZTS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $2.47B; Cost of revenue $673.00M; Selling, general and administrative $592.00M; Income tax $175.00M.
  • 2026-03-31: Revenue $2.26B; Cost of revenue $641.00M; Selling, general and administrative $588.00M; Income tax $157.00M.
  • 2025-12-31: Revenue $2.39B*; Cost of revenue $712.00M*; Selling, general and administrative $619.00M*; Income tax $158.00M*.
  • 2025-09-30: Revenue $2.40B; Cost of revenue $683.00M; Selling, general and administrative $579.00M; Income tax $166.00M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ZTS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.ManufacturedProduct Other$26.00MAnimal HealthDiagnostics$123.00MAnti InfectiveProducts$244.00MCattle$390.00MCompanion Animal$1.71BContract ManufacturingandHuman Health Diagnostics$29.00MDermatology$398.00MDogs And Cats$1.63BFish$83.00MHorses$74.00MLivestock$731.00MOther NonPharmaceuticals$70.00MOther Pharmaceuticals$168.00MPain Sedation$217.00MParasiticides$698.00MPoultry$115.00MSwine$117.00MTotal ProductsandServices$2.44BVaccines$521.00MRevenue$2.47BCost of revenue$673.00MOther income, net-$2.00MSelling, general& administrative$592.00MPre-tax income$866.00MIncome tax$175.00MNet income$691.00M

Geography

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

ZTS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Other DevelopedMarkets$187.00MOther Emerging Markets$269.00MTotalGeographical Area$2.44BAU$94.00MBR$103.00MCA$72.00MCL$34.00MCN$62.00MDE$69.00MES$43.00MFR$40.00MGB$72.00MIT$40.00MJP$41.00MMX$47.00MUS$1.27BRevenue$2.47BCost of revenue$673.00MOther income, net-$2.00MSelling, general& administrative$592.00MPre-tax income$866.00MIncome tax$175.00MNet income$691.00M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueSelling, general and administrativeIncome taxNet income
2026-06-30$2.47B$673.00M$592.00M$175.00M$691.00M
2026-03-31$2.26B$641.00M$588.00M$157.00M$601.00M
2025-12-31$2.39B*$712.00M*$619.00M*$158.00M*$603.00M*
2025-09-30$2.40B$683.00M$579.00M$166.00M$721.00M
2025-06-30$2.47B$664.00M$614.00M$186.00M$726.00M
2025-03-31$2.20B$618.00M$574.00M$171.00M$602.00M
2024-09-30$2.39B$701.00M$565.00M$182.00M$682.00M
2024-06-30$2.36B$668.00M$581.00M$156.00M$624.00M
2024-03-31$2.19B$643.00M$547.00M$148.00M$599.00M
2023-09-30$2.15B$638.00M$525.00M$121.00M$596.00M
2023-06-30$2.18B$607.00M$556.00M$202.00M$671.00M
2023-03-31$2.00B$588.00M$505.00M$146.00M$552.00M
2022-09-30$2.00B$607.00M$501.00M$139.00M$529.00M
2022-06-30$2.05B$625.00M$529.00M$141.00M$529.00M
2022-03-31$1.99B$569.00M$465.00M$133.00M$595.00M
2021-09-30$1.99B$586.00M$504.00M$107.00M$552.00M
2021-06-30$1.95B$568.00M$495.00M$125.00M$512.00M
2021-03-31$1.87B$549.00M$409.00M$129.00M$559.00M
2020-09-30$1.79B$546.00M$424.00M$118.00M$479.00M
2020-06-30$1.55B$451.00M$393.00M$106.00M$377.00M
2020-03-31$1.53B$459.00M$389.00M$74.00M$423.00M
2019-12-31$1.67B(m)(m)$53.00M$384.00M
2019-09-30$1.58B$479.00M$391.00M$95.00M$433.00M
2019-06-30$1.55B$465.00M$406.00M$84.00M$371.00M
2019-03-31$1.46B$518.00M$369.00M$69.00M$312.00M
2018-12-31$1.56B(m)(m)$73.00M$345.00M
2018-09-30$1.48B$473.00M$367.00M$71.00M$347.00M
2018-06-30$1.42B$447.00M$359.00M$55.00M$384.00M
2018-03-31$1.37B$447.00M$338.00M$67.00M$352.00M
2017-12-31$1.46B(m)(m)$350.00M$81.00M
2017-10-01$1.35B$435.00M$328.00M$117.00M$298.00M
2017-07-02$1.27B$440.00M$336.00M$98.00M$247.00M
2017-04-02$1.23B$443.00M$309.00M$98.00M$238.00M
2016-12-31$1.28B(m)(m)$77.00M$154.00M
2016-10-02$1.24B$410.00M$345.00M$96.00M$239.00M
2016-07-03$1.21B$399.00M$343.00M$108.00M$224.00M
2016-04-03$1.16B$389.00M$315.00M$128.00M$204.00M
2015-12-31$1.27B(m)(m)$49.00M$22.00M
2015-09-27$1.21B$421.00M$374.00M$83.00M$189.00M
2015-06-28$1.18B$427.00M$379.00M$9.00M-$37.00M
2015-03-29$1.10B$394.00M$354.00M$65.00M$165.00M
2014-12-31$1.32B(m)(m)$29.00M$126.00M
2014-09-28$1.21B$434.00M$394.00M$71.00M$166.00M
2014-06-29$1.16B$413.00M$396.00M$61.00M$136.00M
2014-03-30$1.10B$379.00M$356.00M$72.00M$155.00M
2013-12-31$1.25B(m)(m)$22.00M$105.00M
2013-09-29$1.10B$385.00M$399.00M$54.00M$131.00M
2013-06-30$1.11B$416.00M$399.00M$59.00M$128.00M
2013-03-31$1.09B$402.00M$357.00M$52.00M$140.00M
2012-12-31$1.18B(m)(m)$84.00M-$10.00M
2012-09-30$1.02B$359.00M$335.00M$52.00M$162.00M
2012-07-01$1.09B$378.00M$344.00M$79.00M$173.00M
2012-04-01$1.05B$393.00M$338.00M$59.00M$111.00M

Revenue and expense 6 month

Period endRevenueCost of revenueSelling, general and administrativeIncome taxNet income
2026-06-30$4.73B$1.31B$1.18B$332.00M$1.29B
2025-06-30$4.67B$1.28B$1.19B$357.00M$1.33B
2024-06-30$4.55B$1.31B$1.13B$304.00M$1.22B
2023-06-30$4.18B$1.20B$1.06B$348.00M$1.22B
2022-06-30$4.04B$1.19B$994.00M$274.00M$1.12B
2021-06-30$3.82B$1.12B$904.00M$254.00M$1.07B
2020-06-30$3.08B$910.00M$782.00M$180.00M$800.00M
2019-06-30$3.00B$983.00M$775.00M$153.00M$683.00M
2018-06-30$2.78B$894.00M$697.00M$122.00M$736.00M
2017-07-02$2.50B$883.00M$645.00M$196.00M$485.00M
2016-07-03$2.37B$788.00M$658.00M$236.00M$428.00M
2015-06-28$2.28B$821.00M$733.00M$74.00M$128.00M
2014-06-29$2.25B$792.00M$752.00M$133.00M$291.00M
2013-06-30$2.20B$818.00M$756.00M$111.00M$268.00M
2012-07-01$2.14B$771.00M$682.00M$138.00M$284.00M

Revenue and expense 9 month

Period endRevenueCost of revenueSelling, general and administrativeIncome taxNet income
2025-09-30$7.08B$1.95B$1.76B$529.00M$2.07B
2024-09-30$6.94B$2.01B$1.69B$486.00M$1.91B
2023-09-30$6.33B$1.83B$1.59B$469.00M$1.82B
2022-09-30$6.04B$1.80B$1.50B$413.00M$1.65B
2021-09-30$5.81B$1.70B$1.41B$361.00M$1.62B
2020-09-30$4.87B$1.46B$1.21B$298.00M$1.28B
2019-09-30$4.59B$1.46B$1.17B$248.00M$1.12B
2018-09-30$4.26B$1.37B$1.06B$193.00M$1.08B
2017-10-01$3.85B$1.32B$973.00M$313.00M$783.00M
2016-10-02$3.61B$1.20B$1.00B$332.00M$667.00M
2015-09-27$3.49B$1.24B$1.11B$157.00M$317.00M
2014-09-28$3.46B$1.23B$1.15B$204.00M$457.00M
2013-09-29$3.31B$1.20B$1.16B$165.00M$399.00M
2012-09-30$3.16B$1.13B$1.02B$190.00M$446.00M

Revenue and expense 12 month

Period endRevenueCost of revenueSelling, general and administrativeIncome taxNet income
2025-12-31$9.47B$2.67B$2.38B$687.00M$2.67B
2024-12-31$9.26B$2.72B$2.32B$637.00M$2.49B
2023-12-31$8.54B$2.56B$2.15B$596.00M$2.34B
2022-12-31$8.08B$2.45B$2.01B$545.00M$2.11B
2021-12-31$7.78B$2.30B$2.00B$454.00M$2.04B
2020-12-31$6.67B$2.06B$1.73B$360.00M$1.64B
2019-12-31$6.26B$1.99B$1.64B$301.00M$1.50B
2018-12-31$5.83B$1.91B$1.48B$266.00M$1.43B
2017-12-31$5.31B$1.77B$1.33B$663.00M$864.00M
2016-12-31$4.89B$1.67B$1.36B$409.00M$821.00M
2015-12-31$4.76B$1.74B$1.53B$206.00M$339.00M
2014-12-31$4.79B$1.72B$1.64B$233.00M$583.00M
2013-12-31$4.56B$1.67B$1.61B$187.00M$504.00M
2012-12-31$4.34B$1.56B$1.47B$274.00M$436.00M
2011-12-31$4.23B$1.65B$1.45B$146.00M$245.00M

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10